Experience the Quality With Free AOCNP Exam Questions That Helps Candidates Pass

Ifosfamide and cyclophosphamide generate the urotoxic metabolite acrolein, which can cause hemorrhagic cystitis. Standard prevention bundles include vigorous IV hydration to dilute and flush acrolein and co-administration of mesna (2-mercaptoethane sulfonate), which binds acrolein in urine and neutralizes its toxicity. Mesna is dosed proportionally to ifosfamide and administered IV or orally on schedules that ensure urinary coverage through the drug’s excretion window. For very high-dose regimens or prior cystitis, continuous bladder irrigation may be added. Antibiotics (Option C) do not prevent chemical cystitis. Loop diuretics alone (Option D) increase urine output but do not neutralize acrolein; omitting mesna is unsafe. Supplements such as cranberry (Option A) lack evidence for this indication. APRN responsibilities include verifying mesna timing relative to ifosfamide, ensuring adequate hydration orders (e.g., normal saline pre/post), monitoring urine output, urinalysis for hematuria, and educating patients to report dysuria, frequency, or clots immediately. If gross hematuria develops, hold offending agents, escalate to urology, manage clots, and consider agents like alum or prostaglandins per institution protocols.

High-risk tumor lysis syndrome (TLS) is predicted by rapidly proliferative tumors with high burden and LDH. Prevention hinges on early, aggressive isotonic IV hydration to enhance renal clearance, avoidance of potassium/phosphate in IV fluids, and frequent laboratory monitoring (K, Ca, Phos, uric acid, creatinine) every 6–8 hours during the risk window. In high-risk patients or those with elevated uric acid, rasburicase rapidly degrades existing uric acid and prevents crystallization in renal tubules; it is superior to allopurinol, which only blocks new uric acid formation and can allow xanthine accumulation. Because rasburicase can cause hemolysis in G6PD deficiency, verify status when possible; if results are pending but risk is extreme, many centers proceed with heightened caution only if prior testing confirms normal G6PD. Routine urine alkalinization (Option C) is no longer recommended due to calcium phosphate precipitation and uncertain benefit. Delaying chemotherapy (Option D) may worsen TLS risk as disease progresses. APRNs coordinate standardized order sets, early nephrology input for patients with renal vulnerability, and clear escalation criteria (diuretics once euvolemic, dialysis for refractory cases).

High-reliability oncology care requires consistent, closed-loop communication at transitions. Standardized handoff frameworks (I-PASS or SBAR) reduce errors by structuring Illness severity/Situation, Patient summary, Action lists, Situation awareness/contingency planning, and Synthesis by receiver (read-back). Protected handoff without interruptions ensures attention to critical details (antibiotic timing, cultures, MASCC risk, red flags). Including contingency plans (“If MAP <65, start norepinephrine”; “If fever recurs, obtain second set of cultures”) prevents ambiguity. Ad hoc hallway updates (Option A) and free-text variability (Option C) increase omissions. Omitting pending items (Option D) undermines continuity. APRNs can lead implementation with education, audit/feedback, and EHR templates, aligning with sepsis bundles and institutional policies. Monitor metrics such as time-to-antibiotic, missed abnormal vitals, and readmissions to evaluate impact, and refine the process with team input to sustain gains.

Severe hypercalcemia of malignancy (≥14 mg/dL) is a medical emergency. First-line therapy is vigorous isotonic IV fluids to restore intravascular volume and enhance calciuresis. Calcitonin provides rapid (but transient) reduction in calcium within hours—useful while definitive agents take effect. IV bisphosphonates (zoledronic acid or pamidronate) inhibit osteoclast-mediated bone resorption and produce sustained correction over 2–4 days. Denosumab is effective when bisphosphonates are contraindicated (renal failure) or ineffective. Loop diuretics (Option C) should only be considered after euvolemia is achieved to avoid worsening dehydration. Steroids (Option D) help in calcitriol-mediated hypercalcemia (e.g., certain lymphomas) but are not sufficient for common osteolytic mechanisms. The APRN should place the patient on cardiac monitoring, track urine output and electrolytes (beware hypophosphatemia/magnesemia), address underlying drivers (tumor control), and educate on hydration and medication effects. Early palliative interventions for symptoms (nausea, constipation, confusion) improve comfort while definitive therapy works.

Prevention data for CIPN are limited, but several randomized and pragmatic studies show benefit from limb cooling (cryotherapy) during taxane infusion, likely by reducing local blood flow and drug delivery to peripheral nerves. Cooling gloves/socks applied shortly before and throughout infusion (and shortly after) have been associated with lower rates of numbness, tingling, and functional impairment, with minimal risk when monitored for frost injury. Exercise programs (aerobic/resistance) may also reduce symptom severity and improve function. Routine calcium/magnesium (Option A) lacks consistent efficacy and is not recommended. High-dose vitamin E (Option C) shows inconsistent or negative results and may interact with therapy. Duloxetine (Option D) is first-line for TREATMENT of painful established CIPN, not prevention. The APRN should educate on proper fit and monitoring of cooling devices, document baseline neuropathy, review comorbid risks (diabetes), and ensure early dose/schedule adjustments for neuropathy progression to preserve function without compromising oncologic outcomes.